Elacestrant (RAD1901) for Metastatic ER+ Advanced Breast Cancer - 102164

Spotlight
Video

Elacestrant (RAD1901) for Metastatic ER+ Advanced Breast Cancer

Loading........
Description: Aditya Bardia, MD, MPH of Harvard Medical School and Massachusetts General Hospital Cancer Center gives an overview of his presentation, Evaluation of RAD1901, a novel investigational, selective estrogen receptor degrader (SERD), for the treatment of ER-positive (ER+) advanced breast cancer, which was presented at the 2017 ASCO Annual Meeting in Chicago, IL.

Abstract 1014: Evaluation of RAD1901, a novel investigational, selective estrogen receptor degrader (SERD), for the treatment of ER-positive (ER+) advanced breast cancer
Shared By : AnnualMeeting2017
Posted on : 06/12/17
Added : 11 months ago
Category : Breast Cancer